FER 13 2006
510(K) Summa
Submitter: Cynosure, Inc. >
5 Carlisle Road K O gS 3 @ Q
Westford, MA 01886

Contact: George Cho —_—_—
Senior Vice President of Medical Technology

Date Summary Prepared: December 21, 2005 :

Device Trade Name: Cynosure PhotoGenica V-Star Laser

Common Name: Medical Laser System

Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.4810

Equivalent Device: Cynosure PhotoGenica VLS-Star Laser

Device Description: The Cynosure PhotoGenica V-Star laser is a pulse dye laser. having an
organic dye as a lasing medium.

Laser activation is by footswitch or finger switch. Overall weight of
the laser is 285Ibs. and the size is 44°x19°x24" (HxWxD).
Electrical requirement is 220 VAC. 30A. 50-60 Hz. single phase.

Intended Use: The Cynosure PhotoGenica V-Star Laser is indicated for benign
vascular and vascular dependent lesion removal. and the treatment of
benign epidermal pigmented lesions.

Comparison: The Cynosure PhotoGenica V-Star Laser has the same indications for
use. the same principle of operation. and similar wavelengths and
pulse energy range as the predicate device(s).

Nonclinical Performance Data: none

Clinical Performance Data: none

Conclusion: The Cynosure PhotoGenica V-Star Laser is a safe and effective device
for the indications specified.

Additional Information: none

: . M6 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
SO
. rok Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
FEB 1 3 2006
Mr. George Cho
Senior Vice President
Medical Technology
Cynosure, Inc.
5 Carlisle Road
Westford, Massachusetts 01886
Re: K053608
Trade/Device Name: Cynosure PhotoGenica V-Star Laser
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in
dermatology
Regulatory Class: II
Product Code: GEX
Dated: December 22, 2005
Received: December 27, 2005
Dear Mr. Cho:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
Lf your device is classified (see above) into either class II (Special Controls) or class {11 (PMA).
it may be subject to such additional controls. Existing major regulations affecting your device
can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA
may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination docs not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other F ederal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Mr. Cho
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your
device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21 CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/cdrh/industry/support/ index.html.

Sincerely yours,

Mark N. Melkerson

Acting Director

Division of General, Restorative

and Neurological, Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure

510(k) Number (if known): K 0 £ s b DX
Device Name: _ Cynosure PhotoGenica V-Star Laser
Indications For Use:
General Surgery: Photocoagulation of benign cutaneous vascular and vascular dependent
lesions and benign cutaneous lesions.
Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesions, such as
facial
and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma,
Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and
psoriasis and the treatment of wrinkles. Treatment of Benign Epidermal Pigmented
Lesions.
Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesions and benign vascular lesions
in
gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
Prescriptive Use x OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation(ODE)
Cuntiare Prueliw

(Division Sign-Off)

Division of General, Restorative,

and Neurological Devices

04
510(k) Number_L0S 5 ©

